Results 31 to 40 of about 5,124 (246)

Erratum: Updates on idarucizumab [PDF]

British Dental Journal, 2017
openaire   +3 more sources

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis [PDF]

New England Journal of Medicine, 2017
BACKGROUND: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. METHODS: We performed a multicenter, prospective, open-label study to determine whether 5 g of intravenous idarucizumab would be ...
C. Pollack, P. Reilly, J. van Ryn, J. Eikelboom, S. Glund, R. Bernstein, R. Dubiel, M. Huisman, E. Hylek, C. Kam, P. Kamphuisen, J. Kreuzer, J. Levy, G. Royle, F. Sellke, J. Stangier, T. Steiner, P. Verhamme, Bushi Wang, L. Young, J. Weitz   +20 more
semanticscholar   +4 more sources

Limitations of idarucizumab efficacy in acute renal failure - a case report [PDF]

Klinická farmakologie a farmacie, 2023
Jitka Rychlíčková, T Trávnícek, Tereza Jelínková, Jan Žák   +3 more
openalex   +2 more sources

Corrigendum to “Sonorheometry parameters during dabigatran reversal with idarucizumab for major bleeding” [The Journal of Pharmacology and Experimental Therapeutics 392 (2025) 103605]

Journal of Pharmacology and Experimental Therapeutics
Dorian Teissandier, Geoffroy Rousseau, Camille Lucchini, Boris Teulade, Camille Joly, Jeannot Schmidt, Bruno Pereira, Aurélien Lebreton, Farès Moustafa   +8 more
openalex   +3 more sources

2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri-operative and bleeding management. [PDF]

Intern Med J
Abstract Direct oral anticoagulants (DOACs) are widely prescribed to prevent and treat venous and arterial thromboembolism, supported by published evidence, and are preferred over warfarin in many guidelines. Although the risk of major bleeding, in particular intracranial haemorrhage (ICH), is decreased with DOACs, gastrointestinal bleeding is ...
Tran HA, Merriman E, Baker R, Curnow J, Young L, Tan CW, McRae S, Chunilal SD.   +7 more
europepmc   +2 more sources

Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?

Trauma Case Reports, 2021
Dabigatran is an oral anticoagulant directly acting as thrombin inhibitor. The monoclonal antibody idarucizumab was developed to reverse its anticoagulatory effects after application of a standardized dose.
Mathias Ströhle, Christopher Rugg, Stefan Schmid, Dietmar Fries, Elgar Oswald   +4 more
doaj   +1 more source

The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation

Scientific Reports, 2021
Dabigatran interferes with many coagulation tests. To overcome this obstacle the use of idarucizumab as an in vitro antidote to dabigatran has been proposed.
Mojca Božič Mijovski, Rickard E. Malmström, Nina Vene, Jovan P. Antovic, Alenka Mavri   +4 more
doaj   +1 more source

[Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy] [PDF]

, 2016
BACKGROUND: Each drug therapy with an anticoagulant effect may require, in emergency conditions, a rapid and specific strategy for a prompt restoration of coagulation.
Andrea Belisari, Sergio Iannazzo, Giuseppe Di Pasquale, Claudio Fresco, LG Mantovani, Maria Pia Ruggeri, Danilo Toni, Raffaele Landolfi   +7 more
openalex   +5 more sources

Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

Cardiology and Therapy, 2020
Introduction Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016.
Masahiro Yasaka, Hiroyuki Yokota, Michiyasu Suzuki, Hidesaku Asakura, Teiichi Yamane, Yukako Ogi, Kaori Ochiai, Daisuke Nakayama   +7 more
doaj   +1 more source

Intravenous thrombolysis following dabigatran reversal in a patient with acute embolic stroke after atrial fibrillation ablation. [PDF]

J Arrhythm
This case demonstrated the feasibility of administering emergent intravenous thrombolysis followed by Dabigatran reversal with idarucizumab in a patient who underwent atrial fibrillation ablation. The consideration of transitioning anticoagulant therapy to dabigatran for scheduled AF ablation in patients at high risk of stroke should be carefully ...
Chen YS, Lin CY.
europepmc   +2 more sources